PACB – Pacific Biosciences of California, Inc.
Float Short %
14.03
Margin Of Safety %
Put/Call OI Ratio
0.26
EPS Next Q Diff
-0.01
EPS Last/This Y
0.57
EPS This/Next Y
0.07
Price
1.16
Target Price
2
Analyst Recom
2.31
Performance Q
-0.85
Relative Volume
1.2
Beta
2.11
Ticker: PACB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | PACB | 1.305 | 0.29 | 0.08 | 100991 |
| 2025-08-18 | PACB | 1.335 | 0.29 | 0.20 | 96440 |
| 2025-08-19 | PACB | 1.305 | 0.29 | 0.02 | 96843 |
| 2025-08-20 | PACB | 1.28 | 0.29 | 0.41 | 97362 |
| 2025-08-21 | PACB | 1.265 | 0.29 | 0.03 | 97621 |
| 2025-08-22 | PACB | 1.385 | 0.29 | 0.02 | 98513 |
| 2025-08-25 | PACB | 1.325 | 0.28 | 0.15 | 99730 |
| 2025-08-26 | PACB | 1.325 | 0.28 | 0.12 | 99566 |
| 2025-08-27 | PACB | 1.325 | 0.28 | 2.22 | 100174 |
| 2025-08-28 | PACB | 1.325 | 0.28 | 0.01 | 100270 |
| 2025-08-29 | PACB | 1.3 | 0.28 | 0.03 | 100774 |
| 2025-09-02 | PACB | 1.285 | 0.28 | 0.01 | 100816 |
| 2025-09-03 | PACB | 1.265 | 0.27 | 0.01 | 101839 |
| 2025-09-04 | PACB | 1.235 | 0.27 | 0.00 | 101916 |
| 2025-09-05 | PACB | 1.265 | 0.26 | 0.03 | 107148 |
| 2025-09-08 | PACB | 1.255 | 0.26 | 0.07 | 107610 |
| 2025-09-09 | PACB | 1.305 | 0.26 | 0.05 | 107676 |
| 2025-09-10 | PACB | 1.225 | 0.26 | 0.22 | 108094 |
| 2025-09-11 | PACB | 1.265 | 0.26 | 0.03 | 108509 |
| 2025-09-12 | PACB | 1.165 | 0.26 | 0.24 | 108876 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | PACB | 1.30 | 8.7 | 143.7 | -0.56 |
| 2025-08-18 | PACB | 1.34 | 16.3 | 151.0 | -0.56 |
| 2025-08-19 | PACB | 1.30 | 16.3 | 158.7 | -0.56 |
| 2025-08-20 | PACB | 1.27 | 16.3 | 158.0 | -0.56 |
| 2025-08-21 | PACB | 1.26 | 16.3 | 155.9 | -0.56 |
| 2025-08-22 | PACB | 1.38 | 16.3 | 136.7 | -0.56 |
| 2025-08-25 | PACB | 1.33 | 16.3 | 162.0 | -0.56 |
| 2025-08-26 | PACB | 1.32 | 16.3 | 155.2 | -0.56 |
| 2025-08-27 | PACB | 1.33 | 16.3 | 153.8 | -0.56 |
| 2025-08-28 | PACB | 1.33 | 16.3 | 155.9 | -0.56 |
| 2025-08-29 | PACB | 1.30 | 16.3 | 158.7 | -0.56 |
| 2025-09-02 | PACB | 1.28 | 16.3 | 158.0 | -0.56 |
| 2025-09-03 | PACB | 1.27 | 16.3 | 371.9 | -0.56 |
| 2025-09-04 | PACB | 1.24 | 16.3 | 372.7 | -0.56 |
| 2025-09-05 | PACB | 1.27 | 16.3 | 369.6 | -0.56 |
| 2025-09-08 | PACB | 1.25 | 16.3 | 372.4 | -0.56 |
| 2025-09-09 | PACB | 1.30 | 16.3 | 368.5 | -0.56 |
| 2025-09-10 | PACB | 1.23 | 16.3 | 376.1 | -0.56 |
| 2025-09-11 | PACB | 1.26 | 16.3 | 369.0 | -0.56 |
| 2025-09-12 | PACB | 1.16 | 16.3 | 376.6 | -0.56 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | PACB | -1.13 | -22.01 | 15.84 |
| 2025-08-18 | PACB | -1.13 | -21.92 | 15.84 |
| 2025-08-19 | PACB | -1.13 | -21.92 | 15.84 |
| 2025-08-20 | PACB | -0.15 | -21.92 | 15.84 |
| 2025-08-21 | PACB | -0.15 | -21.92 | 15.84 |
| 2025-08-22 | PACB | -0.15 | -21.92 | 15.84 |
| 2025-08-25 | PACB | -0.15 | -18.75 | 15.83 |
| 2025-08-26 | PACB | -0.15 | -18.75 | 15.83 |
| 2025-08-27 | PACB | -0.15 | -18.75 | 15.95 |
| 2025-08-28 | PACB | -0.15 | -18.75 | 15.95 |
| 2025-08-29 | PACB | -0.15 | -18.75 | 15.95 |
| 2025-09-02 | PACB | -0.15 | -18.75 | 15.95 |
| 2025-09-03 | PACB | -0.15 | -18.75 | 15.95 |
| 2025-09-04 | PACB | -0.15 | -18.75 | 15.95 |
| 2025-09-05 | PACB | -0.15 | -18.75 | 15.95 |
| 2025-09-08 | PACB | -0.09 | -18.75 | 15.95 |
| 2025-09-09 | PACB | -0.09 | -18.75 | 15.95 |
| 2025-09-10 | PACB | -0.09 | -18.75 | 15.95 |
| 2025-09-11 | PACB | -0.09 | -18.75 | 14.03 |
| 2025-09-12 | PACB | -0.09 | -18.75 | 14.03 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.13
Avg. EPS Est. Current Quarter
-0.14
Avg. EPS Est. Next Quarter
-0.14
Insider Transactions
-0.09
Institutional Transactions
-18.75
Beta
2.11
Average Sales Estimate Current Quarter
40
Average Sales Estimate Next Quarter
43
Fair Value
Quality Score
18
Growth Score
38
Sentiment Score
2
Actual DrawDown %
97.8
Max Drawdown 5-Year %
-98.2
Target Price
2
P/E
Forward P/E
PEG
P/S
2.25
P/B
5.72
P/Free Cash Flow
EPS
-2.27
Average EPS Est. Cur. Y
-0.56
EPS Next Y. (Est.)
-0.49
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-336.4
Relative Volume
1.2
Return on Equity vs Sector %
-880.9
Return on Equity vs Industry %
-874.6
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.07
EBIT Estimation
376.6
Pacific Biosciences of CalifornSector: Healthcare
Industry: Medical Devices
Employees: 575
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
stock quote shares PACB – Pacific Biosciences of California, Inc. Stock Price stock today
news today PACB – Pacific Biosciences of California, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PACB – Pacific Biosciences of California, Inc. yahoo finance google finance
stock history PACB – Pacific Biosciences of California, Inc. invest stock market
stock prices PACB premarket after hours
ticker PACB fair value insiders trading